Association of −31T>C and −511 C>T polymorphisms in the interleukin 1 beta (IL1B) promoter in Korean keratoconus patients

So-Hee Kim,1 Jee-Won Mok,2,3 Hyun-Seok Kim,2,3 C.K. Joo2,3,4

1Department of Life Science, Catholic University of Korea, Seoul, Korea; 2Laboratory of Ophthalmology and Visual Science, Catholic University of Korea, Seoul, Korea; 3Korea Eye Tissue and Gene Bank, Catholic University of Korea, Seoul, Korea; 4Department of Ophthalmology, St. Mary’s Hospital, Seoul, Korea

Purpose: To investigate the genetic association between unrelated Korean keratoconus patients and interleukin 1 alpha (IL1A), interleukin 1 beta (IL1B), and IL1 receptor antagonist (IL1RN) gene polymorphisms.

Methods: We investigated the association between IL1A (rs1800587, rs2071376, and rs17561), IL1B (rs1143627, rs16944, rs1143634, and rs1143633), and IL1RN (rs419598, rs423904, rs424078, and rs315952, variable number tandem repeat [VNTR]) polymorphisms in 100 unrelated Korean keratoconus patients. One hundred control individuals without any corneal disease were selected from the general population. Polymerase chain reaction (PCR) – restriction fragment length polymorphism (RFLP) analysis and direct sequencing were used to screen for genetic variations in the IL1 gene cluster. Haplotypes for the IL1 gene cluster were constructed using Haploview version 4.0.

Results: We analyzed a total of 12 polymorphic sites in the IL1 gene cluster. Among them, the −511 (rs16944) and −31 (rs1143627) positions in the promoter region of IL1B were significantly different between patient and control groups. The C allele of rs16944 (−511C>T, p=0.022, odds ratio of risk [OR]=1.46, 95% confidence intervals [CI] 0.94<2.27) and the T allele of rs1143627 (−31T>C, p=0.025, OR=1.43, 95% CI 0.92<2.22) were associated with a significantly increased risk of keratoconus in Korean patients. Linkage of the two alleles, −31*C and −511*T, was associated with an increased risk for keratoconus with OR=2.38 (p=0.012, 95% CI=1.16–5.046). The *C/*A genotype of rs2071376 in IL1A intron 6 was significantly different between the keratoconus patients and control subjects (p=0.034, OR=0.59, 95% CI 0.32<1.11). Other polymorphisms did not show an association with keratoconus risk.

Conclusions: This is the first report of IL1 gene cluster mutation screening in Korean keratoconus patients. Significant differences in allelic frequency of IL1B between keratoconus patients and the control group suggest that IL1B polymorphisms may play a role in the susceptibility of unrelated Koreans to develop keratoconus.

Keratoconus (OMIM 148300) is a bilateral, asymmetric, chronic, progressive ectasia of the cornea characterized by the steepening and distortion of the cornea, thinning of the apical cornea, and corneal scarring, which leads to progressive myopic and irregular astigmatism [1-3]. Histologically, the keratoconic corneal stroma may become less than one-quarter its normal thickness thereby leading to extensive distortion [4]. The pathophysiological processes underlying the keratoconic cornea have yet to be fully elucidated, although several studies have suggested that keratoconus is associated with eye rubbing in atopic patients [2,5], contact lens wearing [6], increased proteinase activity [4,7], decreased levels of proteinase inhibitors [8-10], increased oxidative damage [11], and keratocyte apoptosis [12,13].

Keratocyte apoptosis has been reported in 60% of keratoconic corneas and is triggered by the epithelial release of interleukin 1 (IL1), which is activated by chronic mechanical injury to the corneal epithelium [12,14]. More specifically, IL1 has been implicated as a damage mediator, which is a modulator that regulates the apoptotic process [15, 16], in these eye rubbers. In addition, stromal thinning in keratoconus is caused by the stimulation of keratocyte apoptosis induced by IL1. For these reasons, IL1 has been suggested as a candidate gene for keratoconus.

IL1 is a pleiotropic cytokine. It is involved in the inflammatory response, cell growth, and tissue repair in the cortex. The IL1 superfamily consists of three members, IL1 alpha (IL1α), IL1 beta (IL1β, predominant form) and IL1 receptor antagonist (IL1Ra), which are encoded by IL1A, IL1B, and IL1RN, respectively [17,18]. The IL1 superfamily genes are located in tandem in a cluster on chromosome 2q14. This gene cluster contains several polymorphisms [19]. Among them, some polymorphisms are located within the regulatory regions of the genes. Their localization in regulatory regions suggests that they may modulate IL1 protein production by directly affecting transcription, leading to their association with altered levels of IL1 [18,20-22].

The goal of this study was to elucidate whether polymorphisms in IL1A, IL1B, and IL1RN are associated with keratoconus in Korean patients. We determined the genotype
frequencies of 11 single nucleotide polymorphisms (SNPs), which were associated with altered levels of cytokines, and one variable number tandem repeat (VNTR) marker in the IL1 gene cluster in unrelated Korean keratoconus patients. Identification of genetic factors that determine susceptibility to keratoconus in Korean patients may allow us to gain insight into the pathogenesis of keratoconus.

**METHODS**

This study included 100 unrelated keratoconus patients of Korean descent with age ranging from 18 to 33 years old. All of the keratoconus patients were identified from the Korea Eye Tissue and Gene Bank related to Blindness in the Department of Ophthalmology at the Catholic University of Korea (Seoul, Korea). Appropriate informed consent was obtained from each subject, and all studies were performed according to the tenets of the Declaration of Helsinki. The patients were diagnosed with keratoconus based on the following criteria: (1) symptoms of keratoconus including the Munson sign, protrusion, Vogt’s striae, corneal thickness, scarring, the Fleischer ring, signs of photokeratoscopy, signs of videokeratography, and refractive errors and (2) medical histories including age, sex, contact lens use, eye rubbing behavior, systemic disease, atopy, and connective tissue disease [2,23]. One hundred age-matched control individuals with no history of keratoconus were also enrolled from the Korea Eye Tissue and Gene Bank related to Blindness.

DNA was extracted from peripheral blood samples using the QIAamp DNA blood kit (QIAGEN, Valencia, CA). Polymerase chain reaction (PCR) reactions were performed with 25 ng of genomic DNA as a template in a mixture of PCR buffer, 2.5 mM MgCl₂, 200 nM dNTPs, 0.4 pmol of each primer, and 0.75 units of h-Taq polymerase (Solgent, Daejeon, Korea; Table 1) [19,24,25].

Biallelic polymorphisms in the IL1 gene cluster were determined by PCR–restriction fragment length polymorphism (RFLP) analysis and direct sequencing (Table 1). The IL1RN VNTR polymorphism was evaluated by identifying the number of repeats in the (86)n sequence using agarose gel electrophoresis and direct sequencing [19,24,25].

The Hardy–Weinberg equilibrium (HWE) was calculated using the GenePop web version 4.0 program. To determine statistically significant differences in genotype and allele frequencies between the two groups, we used the χ2 test or Fisher’s exact test for the 2×2 contingency table file. The descriptive statistics for observed differences in allele or genotype distribution with the corresponding p values were analyzed using the JavaStat web software in combination with StatXact-8 software (Cytel Inc., Cambridge, MA). The strength of the association was estimated by odds ratio of risk (OR) and 95% confidence intervals (CI). Haplotype frequencies and associations were calculated with Haploview (version 4.0) that uses the expectation maximization (EM) algorithm [26]. Haplotype distributions were evaluated by the permutation test on the basis of 10,000 replications to obtain the empirical significance [26]. Values of p<0.05 were considered statistically significant.

**RESULTS**

We analyzed 11 SNPs and one VNTR marker in the IL1 gene cluster: rs1800587, rs2071376, and rs17561 for IL1A; rs1143627, rs16944, rs1143634, and rs1143633 for IL1B; and rs419598, rs423904, rs424078, rs315952, and the (86)n VNTR marker for IL1RN (Figure 1). The IL1A, IL1B, and IL1RN genotypic and allelic frequencies in keratoconus patients are listed in Table 2 and Table 3. The genotype distributions of the variants of the 12 polymorphisms in the

---

**TABLE 1. POLYMORPHIC SITES OF IL1A, IL1B, AND IL1RN.**

| Gene | Nucleotide | SNPs | dbSNPs | Amino acid | Assay methoda | Genotypesb |
|------|------------|------|--------|------------|---------------|------------|
| IL1A | exon 1     | −889 C>T | Ex1+12C>T | rs1800587 | RFLP: DpnII *c: 170bp | *t: 145+25bp |
|      | exon 5     | +4845 G>T | Ex5+21G>T | rs17561 | RFLP: Sall *G:29+123+3+84bp | *t: 152+3+84bp |
|      | intron 6   | +576 C>A | IVS6+169C>A | rs2071376 | RFLP: BstYI *c:270bp | *a: 198+72bp |
| IL1B | promoter   | −511C>T | T−511T>C | rs16944 | RFLP: Avel *t:530bp | *c:190+340bp |
|      | promoter   | −31 T>C | C−31 C>T | rs1143627 | Direct sequencing | |
|      | intron 4   | +5810 G>A | IVS4+64G>A | rs1143633 | RFLP: Fnu4HI *g:38+271+19bp | *a:309+19bp |
|      | exon 5     | +3954C>T | Ex5+14C>T | rs1143634 | F105F | |
| IL1RN| exon 4     | +8006 C>T | EX4+55C>T | rs419598 | A60A | |
|      | intron 4   | +8061 C>T | IVS4+21C>T | rs423904 | RFLP: HpalI *C: 29+98 bp | *T: 127 bp |
|      | intron 4   | 86bp VNTR | | | | |
|      | intron 5   | +9589A>T | IVS5+59A>T | rs454078 | RFLP: SspI *a:299bp | *t:145+154bp |
|      | exon 7     | +1100T>C | Ex7+72T>C | rs315952 | RFLP: MspA1I *T:330bp | *C:132+190bp |

Assay methoda: Screening method for polymorphic site and lists of restriction enzyme; Agarose: Agarose gel electrophoresis; Genotypesb: It was indicated restricted sizes by RFLP analysis and amplified products for VNTR.
gene cluster among the control subjects and the keratoconus patients were in Hardy–Weinberg equilibrium. Of the four SNPs in IL1B, the rs1143627 (−31T>C) and rs16944 (−511C>T) positions in the promoter region of IL1B were polymorphic.

Table 2. Genotype frequencies of IL1A and IL1B in keratoconus patients.

| Genes | SNPs       | Genotypes | Keratoconus | Control | p value |
|-------|------------|-----------|-------------|---------|---------|
| IL1A  | −889 C>T (rs1800587) | C/C | 87.2        | 88.6    | N.S.    |
|       |            | T/C | 11.7        | 10      | N.S.    |
|       |            | T/T | 1.1         | 1.4     | N.S.    |
|       | +4845 G>T (rs17561) | G/G | 75.8        | 81.4    | N.S.    |
|       |            | T/G | 23.2        | 17.1    | N.S.    |
|       |            | T/T | 1.1         | 1.4     | N.S.    |
|       | +376 C>A (rs2071376) | A/A | 11.7        | 8.6     | N.S.    |
|       |            | C/A | 37.2        | 50      | 0.034*  |
|       |            | C/C | 51.1        | 41.4    | N.S.    |
| IL1B  | −511C>T (rs16944) | C/C | 34.8        | 21.4    | 0.025** |
|       |            | T/C | 43.5        | 51.5    | N.S.    |
|       |            | T/T | 21.7        | 27.1    | N.S.    |
|       | −31 T>C (rs1143627) | C/C | 23.7        | 28.6    | N.S.    |
|       |            | T/C | 41.9        | 50      | N.S.    |
|       |            | T/T | 34.4        | 21.4    | 0.027***|
|       | +5810G>A (rs1143633) | A/A | 39.8        | 45.7    | N.S.    |
|       |            | G/A | 39.8        | 35.7    | N.S.    |
|       |            | G/G | 20.4        | 18.6    | N.S.    |
|       | +3954C>T (rs1143634) | C/C | 92.5        | 95.7    | N.S.    |
|       |            | T/C | 6.5         | 2.9     | N.S.    |
|       |            | T/T | 1.1         | 1.4     | N.S.    |

The asterisk indicates that OR=0.59 and 95% CI=0.32<1.11. The double asterisk indicates that OR=1.96 and 95% CI=0.96<3.96. The triple asterisk indicates that OR=1.92 and 95% CI=0.95<3.90. N.S., not significant.

**IL1** gene cluster among the control subjects and the keratoconus patients were in Hardy–Weinberg equilibrium. Of the four SNPs in **IL1B**, the rs1143627 (−31T>C) and rs16944 (−511C>T) positions in the promoter region of **IL1B**.
were significantly different between the patient and control groups. For rs16944 (−511 T>C), the frequency of the *C/*C genotype was higher in the patients (34.8%) than in control subjects (21.4%; \( p=0.025, \text{OR}=1.96, 95\%\ CI \ 0.96<3.96 \)). The *C allele frequency at rs16944 was also higher in the patients (56.5%) than in the control subjects (47.1%; \( p=0.022, \text{OR}=1.46, 95\%\ CI \ 0.94<2.27 \)). The distribution of rs1143627 (−31C>T) *T/*T, *T/*C, and *C/*C genotype frequencies were 34.4, 41.9, and 23.7, respectively, in keratoconus patients and 21.4, 50.0, and 28.6, respectively, in control subjects. The *T/*T genotype frequency had a higher risk of occurring in keratoconus patients than in control subjects (\( p=0.027, \text{OR}=1.92, 95\%\ CI \ 0.95<3.90 \)). The allele frequency of *T was 55.4% in keratoconus patients and 46.4% in control subjects (\( p=0.025, \text{OR}=1.43, 95\%\ CI \ 0.92<2.22 \)).

Of the three SNPs in \( IL1A \), the *C/*A genotype for rs2071376 in intron 6 was significantly different between keratoconus patients and control subjects (\( p=0.034, \text{OR}=0.59, 95\%\ CI \ 0.32<1.11 \)), but the allele frequencies were not significantly different between the groups. Other SNPs and the VNTR showed no significant genotype or allele frequency differences between keratoconus patients and control subjects.

In the haplotype analysis, we identified three haplotype block sets, rs2071376-rs17561-rs1800587-rs1143634 for Block A, rs1143627-rs16944 for Block B, and rs419598-rs423904-rs454078 for Block C (Figure 2). The T-C haplotype in Block B was more prevalent in keratoconus patients than in control subjects and was associated with a higher risk of developing keratoconus (\( p=0.034, \text{OR}=1.58, 95\%\ CI \ 1.018<2.448 \)). In contrast, the T-T haplotype in Block B was less frequent in the keratoconus group compared with the control group (\( p=0.009; \text{Table 4} \)).

**DISCUSSION**

Keratoconus is an abnormality of the interactive epithelial-stromal system that causes a shift in the delicate balance between keratocyte proliferation and apoptosis [12]. Using the TUNEL assay, Kim et al. [12] confirmed the presence of keratocyte apoptosis in keratoconus corneas and the absence of keratocyte apoptosis in normal corneas. Keratocyte apoptosis may be triggered by increased basal IL1 release [12,14,27]. Previous studies indicated that corneal fibroblasts from keratoconus patients express about three times more \( IL1A \) mRNA than those from a normal cornea [15,28]. Zhou et al. [29] reported that the IL1 protein level was higher in the epithelium and endothelium of the keratoconus corneas than in normal corneas. In addition, IL1 upregulates keratocyte expression of collagenses, metalloproteinases, and other enzymes [30,31]. These enzymes have important roles in the remodeling of collagen during corneal wound healing. For
example, persistent rubbing of the eye is likely to produce corneal epithelial trauma and increase the release of IL1 [15, 16,32,33]. This would provide a unifying explanation for the association between keratoconus and factors associated with mechanical corneal epithelial cell injury such as poorly fitted rigid contact lenses, excessive eye rubbing, and allergic ocular surface disease [2,4,5,34]. Therefore, it has been suggested that interleukins are central modulators of the response to corneal injury.

The IL1 superfamily includes three secreted glycoproteins, IL1α, IL1β, and IL1Ra. Two of these, IL1α and IL1β, are biologically active while the third member, IL1Ra, is a receptor antagonist that modulates the effects of IL1α and IL1β [18,19]. IL1α and IL1β proteins are synthesized by a

---

**Table 4. Haplotype Analysis of the Interleukin 1 Genes in Keratoconus Patients.**

| Block     | Haplotype                                      | Case:Control frequency | χ²   | p value |
|-----------|------------------------------------------------|-------------------------|------|---------|
| Block 1   | rs2071376-rs17561-rs1800587-rs1143634          |                         |      |         |
|           | CGCC                                           | 0.656:0.634             | 0.168| 0.682   |
|           | AGCC                                           | 0.217:0.266             | 1.031| 0.309   |
|           | ATTT                                           | 0.042:0.029             | 0.421| 0.516   |
|           | CTCC                                           | 0.041:0.030             | 0.281| 0.596   |
|           | ATTC                                           | 0.032:0.036             | 0.043| 0.836   |
| Block 2   | rs1143627-rs16944                              |                         |      |         |
|           | TC                                             | 0.556:0.442             | 4.161| 0.034*  |
|           | CT                                             | 0.394:0.492             | 3.176| 0.075   |
|           | CC                                             | 0.049:0.029             | 0.813| 0.367   |
|           | TT                                             | 0.001:0.037             | 6.168| 0.009** |
| Block 3   | rs419598-rs423904-rs454078                      |                         |      |         |
|           | TCA                                            | 0.916:0.929             | 0.181| 0.67    |
|           | CTT                                            | 0.074:0.064             | 0.11 | 0.74    |

The asterisk indicates that OR=1.58 and 95% CI=1.018<2.448, and the double asterisk indicates that OR=0.04 and 95% CI=0.003<0.667.
variety of cell types including activated macrophages, stimulated B lymphocytes, fibroblasts, and endothelial cells. They are powerful mediators of inflammation and the immune response. *IL1A*, *IL1B*, and *IL1RN* map to human chromosome 2q14. Gene variations that alter gene function are more likely to influence phenotypic characteristics such as risk of disease [18]. An in vivo study showed that the *IL1A*-889*T* allele was associated with increased IL1α and IL1β protein levels. Furthermore, ex vivo analysis of lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells indicated that production of IL1α from *IL1A* with the *IL1A*-889*T* allele increased [35,36]. The two promoter variants of *IL1B*, −511*C>T* and −31*T>C* SNPs, have been repeatedly associated with multiple clinical conditions [37,38] such as cardiovascular disease [39] and gastric cancer [40] as well as with clinically observed differences in the levels of IL1β protein in vivo [39,41]. The *T* allele at −31 in the TATA box of the *IL1B* promoter region is suspected to enhance gene expression and induction of IL1β [42]. The −31*C* allele was associated with increased IL1β levels and decreased IL1α levels [43]. It has been reported that the T and C variants at the *IL1B* −31 position regulate gene expression and differential binding of proteins. A specific haplotype, which is composed of the T allele at −511 and the C allele at −31, was significantly associated with a twofold to threefold increase in LPS-induced IL1β protein secretion [21]. There was also nearly a complete linkage disequilibrium between −511*C>T* and −31*T>C* in *IL1B* based on a cis interaction [40,42].

Some studies have suggested that the allelic polymorphism located within intron 2 of *IL1RN* play a role in differential modulating IL1 activity. The *IL1RA*+2 is associated with increased IL1Ra protein production in vitro [44]. The *C* allele of +8006 C/T in exon 2 of *IL1RN* is associated with the VNTR allele 2 and is associated with lower expression of IL1Ra [45,46]. The *IL1B*+511*C*, *IL1B*-31*T*, and *IL1RN*+8006*T* haplotype (C-T-T), which has been associated with lower levels of IL1β expression [21,38], was present in the extended protective haplotype. This extended protective haplotype contains the *IL1RN*+8006*T* allele, which is associated with elevated IL1Ra expression [45]. Therefore, these studies suggest that *IL1* gene cluster polymorphisms may affect susceptibility to the development of specific diseases and that linkage disequilibrium of functional polymorphisms may indicate increased risk of developing these diseases.

In the present study, we have reported the results of a mutation screening of interleukin 1 genes in unrelated Korean patients with keratoconus. In the screen of four SNPs of *IL1B*, the genotypes of −511*C>C* and −31*T*T* of *IL1B* SNPs were associated with a 1.96 fold and 1.92 fold greater risk of developing keratoconus, respectively, (p=0.025 and p=0.027, respectively), showing a strong statistical association with keratoconus in unrelated patients. Two *IL1B* SNPs, −31*C>T* and −511*T*C, have been implicated as potential risk factors for keratoconus among unrelated patients. Of the three SNPs in *IL1A*, the *C>A* genotype of rs2071376 in intron 6 differed significantly between the keratoconus patients and control subjects (p=0.034, OR=0.59, 95% CI 0.32<1.11), but the allele frequencies were not significantly different between the groups.

The T-C haplotype of *IL1B* −31 and −511 was more prevalent in keratoconus patients than in control subjects and carried a higher risk of keratoconus (p=0.034, OR=1.58, 95% CI 1.018<2.448). The T-T haplotype of *IL1B*-31 and −511 was less frequent in keratoconus patients than in the control individuals (p=0.009), which was associated with protection.

Our study is the first to report on *IL1* gene cluster polymorphisms in Korean keratoconus patients. We detected two disease-associated SNPs, rs1143627 (−31>T>C) and rs16944 (−511>C>T), in *IL1B* and a disease-associated haplotype, the *IL1B*-31*T*-511*C* haplotype, which is associated with regulation of IL1α and IL1β production. It proves that IL1 may have important roles as central modulators of keratoconus development. In conclusion, the present study suggests that two SNPs in *IL1B* predict keratoconus predisposition in unrelated Korean patients, although further research is necessary to elucidate the relationship between the expression levels of IL1α, IL1β, and IL1Ra and SNPs of *IL1B* in keratoconus patients.

ACKNOWLEDGMENTS

The authors thank the Korea Eye Tissue and Gene Bank at the Catholic University of Korea and the staff of the Department of Ophthalmology at St. Mary’s Hospital. The authors thank M. Hwang for useful discussion.

REFERENCES

1. Krachmer JH, Feder RS, Belin MW. Keratoconus and related noninflammatory corneal thinning disorders. Surv Ophthalmol 1984; 28:293-322. [PMID: 2197100]
2. Rabinowitz YS. Keratoconus. Surv Ophthalmol 1998; 42:297-319. [PMID: 9493273]
3. Bron AJ. Keratoconus. Cornea 1988; 7:163-9. [PMID: 3048880]
4. Cristina Kenney M, Brown DJ. The cascade hypothesis of keratoconus. Cont Lens Anterior Eye 2003; 26:139-46. [PMID: 16303509]
5. Bawazer AM, Hodge WG, Lorimer B. Atopy and keratoconus: a multivariate analysis. Br J Ophthalmol 2000; 84:834-6. [PMID: 16006086]
6. Maesai MS, Varley GA, Krachmer JH. Development of keratoconus after contact lens wear. Arch Ophthalmol 1990; 108:534-8. [PMID: 2322155]
7. Brown D, Chwa MM, Opbroek A, Kenney MC. Keratoconus corneas: increased gelatinolytic activity appears after modification of inhibitors. Curr Eye Res 1993; 12:571-81. [PMID: 8359032]
8. Sawaguchi S, Twining SS, Yue BY, Wilson PM, Sugar J, Chan SK. Alpha-1 proteinase inhibitor levels in keratoconus. Exp Eye Res 1990; 50:549-54. [PMID: 2197100]
9. Opbroek A, Kenney MC, Brown D. Characterization of a human corneal metalloproteinase inhibitor (TIMP-1). Curr Eye Res 1993; 12:877-83. [PMID: 7507419]

10. Zhou L, Sawaguchi S, Twining SS, Sugar J, Feder RS, Yue BY. Expression of degradative enzymes and protease inhibitors in corneas with keratoconus. Invest Ophthalmol Vis Sci 1998; 39:1117-24. [PMID: 9620070]

11. Buddi R, Lin B, Attilano SR, Zarapapal NC, Kenney MC, Brown DJ. Evidence of oxidative stress in human corneal diseases. J Histochem Cytochem 2002; 50:341-51. [PMID: 11850437]

12. Kim WJ, Rabinowitz YE, Meisler DM, Wilson SE. Keratoocyte apoptosis associated with keratoconus. Exp Eye Res 1999; 69:475-81. [PMID: 10548467]

13. Wilson SE, Kim WJ. Keratocyte apoptosis: implications on corneal wound healing, tissue organization, and disease. Invest Ophthalmol Vis Sci 1998; 39:220-6. [PMID: 9477978]

14. Wilson SE, He YG, Weng J, Li Q, McDowell AW, Vital M, Chwang EL. Epithelial injury induces keratocyte apoptosis: hypothesized role for the interleukin-1 system in the modulation of corneal tissue healing and wound organization. Exp Eye Res 1996; 62:325-7. [PMID: 8795451]

15. Fabre EJ, Bureau J, Pouliquen Y, Lorans G. Binding sites for human interleukin 1 alpha, gamma interferon and tumor necrosis factor on cultured fibroblasts of normal cornea and keratoconus. Curr Eye Res 1991; 10:585-92. [PMID: 1914496]

16. Kaldawy RM, Wagner J, Ching S, Seigel GM. Evidence of apoptotic cell death in keratoconus. Cornea 2002; 21:206-9. [PMID: 11862097]

17. Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994; 19:382-4. [PMID: 8188271]

18. Roux-Lombard P. The interleukin 1 family. Eur Cytokine Netw 1998; 9:565-76. [PMID: 9889400]

19. Steinkasserer A, Spurr NK, Cox S, Jeggo P, Sim RB. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics 1992; 13:654-7. [PMID: 1386337]

20. Endres S, Cannon JG, Ghobrani R, Dempsey RA, Sisson SD, Lonnemann G, Van der Meer JW, Wolf SM, Dinarello CA. In vitro production of IL-1beta, IL-1 alpha, TNF and IL-2 in healthy subjects: distribution, effect of cyclooxygenase inhibitor and evidence of independent gene regulation. Eur J Immunol 1989; 19:2327-33. [PMID: 2514105]

21. Hall SK, Perregaux DG, Gabel CA, Woodworth T, Durham LK, Huizinga TW, Breedveld FC, Seymour AB. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum 2004; 50:1976-83. [PMID: 15188375]

22. Kilipinaen S, Huhtala H, Hurme M. The combination of the interleukin-1 alpha (IL-1alpha-899) genotype and the interleukin-10 (IL-10 ATA) haplotype is associated with increased interleukin-10 (IL-10) plasma levels in healthy individuals. Eur Cytokine Netw 2002; 13:66-71. [PMID: 11956022]

23. McMahon TT, Szczotka-Flynn L, Barr JT, Anderson RJ, Slaughter ME, Lass JH, Iyengar SK. CLEK Study Group. A new method for grading the severity of keratoconus: the Keratoconus Severity Score (KSS). Cornea 2006; 25:794-800. [PMID: 17068456]

24. Timms AE, Crane AM, Sims AM, Cordell HJ, Bradbury LA, Abbott A, Coyle MR, Beynon O, Herzberg I, Duft GW, Calin A, Cardon LR, Wordsworth BP, Brown MA. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 2004; 75:587-95. [PMID: 15309690]

25. Cantagrel A, Navaux F, Loubet-Lescoulié P, Nourhashemi F, Enault G, Abbal M, Constantin A, Laroche M, Mazières B. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999; 42:1093-100. [PMID: 10366101]

26. Barrett JC, Fry B, Maller J, Daly MJ. Haplotype: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-5. [PMID: 15297300]

27. Helena MC, Baeveldt F, Kim WJ, Wilson SE. Keratocyte apoptosis following corneal surgery. Invest Ophthalmol Vis Sci 1998; 39:276-83. [PMID: 9477983]

28. Barbaro V, Di Iorio E, Ferrari S, Bisceglia L, Ruzza A, De Luca M, Pellegrini G. Expression of VSX1 in human corneal keratocytes during differentiation into myofibroblasts in response to wound healing. Invest Ophthalmol Vis Sci 2006; 47:5243-50. [PMID: 17122109]

29. Zabaleta J, Camargo MC, Piauzuelo MB, Fontham E, Schneider BG, Sicinschi LA, Ferrante W, Balart L, Correa P, Ochoa AC. Association of interleukin-1beta gene polymorphisms with precancerous gastric lesions in African Americans and Caucasians. Am J Gastroenterol 2006; 101:163-71. [PMID: 16405550]

30. West-Mays JA, Sadow PM, Tobin TW, Strissel KJ, Cintron C, Fini ME. Repair phenotype in corneal fibroblasts is controlled by an interleukin-1 alpha autocrine feedback loop. Invest Ophthalmol Vis Sci 1997; 38:1367-79. [PMID: 9191600]

31. Strissel KJ, Rinehart WB, Fini ME. Regulation of paracrine cytokine balance controlling collagenase synthesis by corneal cells. Invest Ophthalmol Vis Sci 1997; 38:546-52. [PMID: 9040490]

32. Wilson SE, Liu J, Mohan RR. Stromal-epithelial interactions in the cornea. Prog Retin Eye Res 1999; 18:293-309. [PMID: 10192515]

33. Wilson SE, Mohan RR, Mohan RR, Ambrósio R Jr, Hong J, Lee J. The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res 2001; 20:625-37. [PMID: 11470453]

34. Chwa M, Attilano SR, Reddy V, Jordan N, Kim DW, Kenney MC. Increased stress-induced generation of reactive oxygen species and apoptosis in human keratoconus fibroblasts. Invest Ophthalmol Vis Sci 2006; 47:1902-10. [PMID: 15188375]

35. Dominici R, Cattaneo M, Malferrari G, Archi D, Mariani C, Grimaldi LM, Biunno I. Cloning and functional analysis of the transcriptional regulatory region of interleukin-1 alpha. Immunogenetics 2002; 54:82-6. [PMID: 12037600]

36. Shirodaria S, Smith J, McKay IJ, Kennett CN, Hughes FJ. Polymorphisms in the IL-1A gene are correlated with levels of interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999; 42:1093-100. [PMID: 10366101]
of interleukin-1alpha protein in gingival crevicular fluid of teeth with severe periodontal disease. J Dent Res 2000; 79:1864-9. [PMID: 11145356]
37. Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F. Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumonia infection. J Am Coll Cardiol 2001; 38:712-7. [PMID: 11527622]
38. Camargo JF, Correa PA, Castiblanco J, Anaya JM. Interleukin-1beta polymorphisms in Colombian patients with autoimmune rheumatic diseases. Genes Immun 2004; 5:609-14. [PMID: 15470475]
39. Iacoviello L, Di Castelnuovo A, Gattone M, Pezzini A, Assanelli D, Lorenzet R, Del Zotto E, Colombo M, Napoleone E, Amore C, D'Orazio A, Padovani A, de Gaetano G, Giannuzi P, Donati MB. IGIGI Investigators. Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro. Arterioscler Thromb Vasc Biol 2005; 25:222-7. [PMID: 15539626]
40. Chang YW, Jang JY, Kim NH, Lee JW, Lee HJ, Jung WW, Dong SH, Kim HJ, Kim BH, Lee JI, Chang R. Interleukin-1B (IL-1B) polymorphisms and gastric mucosal levels of IL-1beta cytokine in Korean patients with gastric cancer. Int J Cancer 2005; 114:465-71. [PMID: 15551344]
41. Hulkkonen J, Laippala P, Hurme M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Netw 2000; 11:251-5. [PMID: 10903804]
42. Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, Rogus J, Beck JD, Offenbacher S, Cork MJ, Rafie-Kolpin M, Hsieh CM, Kornman KS, Duft GW. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 2006; 15:519-29. [PMID: 16399797]
43. de Jongh CM, Khrenova L, Kezic S, Rustemeyer T, Verberk MM, John SM. Polymorphisms in the interleukin-1 gene influence the stratum corneum interleukin-1 alpha concentration in uninvolved skin of patients with chronic irritant contact dermatitis. Contact Dermatitis 2008; 58:263-8. [PMID: 18416755]
44. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99:303-10. [PMID: 7851026]
45. Carter MJ, di Giovine FS, Jones S, Mee J, Camp NJ, Lobo AJ, Duft GW. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians. Gut 2001; 48:461-7. [PMID: 11247888]
46. Arnalich F, López-Maderuelo D, Codoceo R, López J, Solis-Garrido LM, Capiscol C, Fernandez-Capitán C, Madero R, Montiel C. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002; 127:331-6. [PMID: 11876758]